Thus, the downregulation of PD‐L1 suggests enhanced anti‐tumor immunity. Together, these findings indicate that PRDX1 ablation may suppress CRC development by enhancing anti‐tumor immunity through modulation of macrophage polarization and secretion of inflammatory cytokines. The gene discussed is PRDX1; the disease is colorectal carcinoma.